This appears to be the case in human ovarian clear cell carcinomas and endometrioid endometrial cancers, where the loss of ARID1A appears to be nearly mutually exclusive from TP53 mutations [24, 26]. This evidence concerns the gene TP53 and ovarian clear cell cancer.